Financings In Brief
This article was originally published in The Gray Sheet
Spine Wave raises $45 million: Spinal implant developer Spine Wave raises $45 million in a private placement to support expansion of its U.S. sales force and global distribution network, as well as R&D efforts and clinical trials, the firm says. Shelton, Conn.-based Spine Wave's U.S. offerings include the StaXx XD expandable polyetheretherketone (PEEK) spacer for vertebral body replacement and the CapSure PS top loading pedicle screw system for treating degeneration, tumor, or trauma of the thoracolumbar spine. Outside the United States the firm also offers the StaXx FX minimally invasive system for repairing vertebral compression fractures, and the NuCore injectable nucleus for early-stage degenerative disc disease. Founded in 2001 by former execs of spinal device powerhouse Sofamor Danek, privately held Spine Wave's latest financing round was led by Compass Global Fund...
You may also be interested in...
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.
Sabinsa provided FDA and FTC with documentation of “an ingredient falsely marketed and sold as vitamin C derived from amla fruit (Emblica officinalis), which two independent labs have confirmed is actually derived from corn, sugarcane or other plants.”